Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Mereo BioPharma

- PMLiVE

AZ confirms interest in Acerta takeover

Possible acquisition of Netherlands-based cancer drug developer may be worth more than $5bn

EU flag

Celgene’s Vidaza wins wider approval for acute myeloid leukaemia

Elderly patients to gain access to cancer drug

- PMLiVE

Cancer Drugs Fund axes 16 treatments after overspending

Medicines from Roche, Celgene, Merck KGaA and Janssen among those dropped

- PMLiVE

NICE turns down Celgene’s Otezla once again

Concludes the drug's cost outweighs its benefit for psoriatic arthritis

Celgene building

Myeloma market set to be $9bn by 2021

New research shows it will pushed by a growing prevalence of the disease

- PMLiVE

Bionor gears up for ‘kick and kill’ HIV data

Could also be used in conjunction with Celgene's cancer drug Revlimid

Celgene building

Celgene spends $7.2bn on Receptos purchase

Latest deal forms part of a major spending spree for the firm

Celgene building

Celgene and Juno announce ten-year cancer deal

The firms’ pact will focus on the new area of immunotherapy

Roche Basel Switzerland

Roche maintains dominance as leading cancer drugmaker

But the firm’s growth is stalling as pricing pressures hit sales

- PMLiVE

Celgene’s psoriasis pill gives ‘no added benefit’ to patients

Germany’s cost assessor IQWiG says Otezla is not value for money

- PMLiVE

Michael Zaiac moves from GSK to Celgene

He takes up the role of VP, medical affairs, haematology-oncology EMEA

Celgene building

Celgene to acquire biotech firm Quanticel Pharmaceuticals

Firm hopes to expand its pipeline of life-enhancing products for cancer patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links